论文部分内容阅读
以逆转录多聚酶链反应（ＲＴ－ＰＣＲ）结合溴介导生物素标记寡核苷酸探针杂交（ｄｏｔｂｌｏｔ）对７３例各型、各期白血病细胞中多药耐药（ＭＤＲ１）基因表达进行了检测并以ＭＤＲ１／β２Ｍ（β＿２微球蛋白）对其进行了半定量分析，结果表明在初治、复发及完全缓解急性白血病及慢粒急变白血病中均有ＭＤＲ１阳性检出其表达水平不同，发现临床白血病化疗耐药的发生主要与ＭＤＲ＿１高表达有关，对可作预后评价的病例分析表明ＭＤＲ＿１的高表达与其化疗反应显著相关，认为ＲＴ－ＰＣＲ检测ＭＤＲ＿１基因表达可作为一个临床化疗耐药指标有助于针对性的白血病个体化疗方案的判定。
Multidrug resistance (MDR1) gene expression in 73 leukemia cells of various types and stages was performed by reverse transcription polymerase chain reaction (RT-PCR) coupled with bromine-mediated biotin-labeled oligonucleotide probe hybridization (dotblot) Detected and semi-quantitatively analyzed by MDR1/β2M (β 2 microglobulin), the results showed that in the initial treatment, relapse and complete remission of acute leukemia and chronic myeloid leukemia, MDR1 positive was detected in different expression levels, found that The occurrence of chemotherapy resistance in clinical leukemia is mainly related to the high expression of MDR1. Analysis of cases that can be used to evaluate the prognosis indicates that the high expression of MDR-1 is significantly associated with its chemotherapy response. It is believed that the detection of MDR1 gene expression by RT-PCR can be used as a clinical drug resistance indicator. Assist in the determination of targeted leukemia individual chemotherapy regimens.